Docket #1292 Date Filed: 11/03/2026

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
	)	Case No. 25-12177 (LSS)
Apple Tree Life Sciences, Inc., *et al.*,[1]	)	Jointly Administered
Debtors.	)	**Re: Docket No. 1232**

CERTIFICATE OF NO OBJECTION REGARDING APPLICATION OF DEBTOR ATP LIFE SCIENCE VENTURES, L.P. FOR AN ORDER AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL, EFFECTIVE AS OF SEPTEMBER 28, 2026

I, R. Craig Martin, a partner with DLA Piper LLP (US), as counsel to ATP Life Science Ventures, L.P (the "Fund Debtor"), in the above-captioned chapter 11 cases, certify as follows:

1. On October 19, 2026, the Fund Debtor filed the *Application of Debtor ATP Life Science Ventures, L.P. for an Order Authorizing and Approving the Employment and Retention of Orrick, Herrington & Sutcliffe LLP as Co-Counsel, Effective as of September 28, 2026* [D.I. 1232] (the "Application") with the United States Bankruptcy Court for the District of Delaware (the "Court").

2. The deadline to object to the Application was November 2, 2026 at 4:00 p.m. (ET). The Fund Debtor has not received any response or objection to the Application, and a review of

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

2512177261103000000000005

the docket in these chapter 11 cases indicates that no party has filed any response or objection to the Application as of the date hereof.

WHEREFORE, the Fund Debtor respectfully requests that the Court enter the proposed order filed with the Application and substantially in the form of the order attached hereto as **Exhibit A**, granting the relief requested in the Application and such other and further relief as the Court deems just and proper.

Dated: November 3, 2026
Wilmington, Delaware

Respectfully submitted,

DLA PIPER LLP (US)

/s/ R. Craig Martin
R. Craig Martin (DE No. 5032)
DLA Piper LLP (US)
1201 North Market Street, Suite 2100
Wilmington, Delaware 19801
Telephone: (302) 468-5700
Facsimile: (302) 394-2341
Email: craig.martin@us.dlapiper.com

-and-

Gregory M. Juell (NY No. 5420120)
1251 Avenue of the Americas
New York, New York 10020
Telephone: (212) 335-4000
Facsimile: (212) 335-4501
Email: gregory.juell@us.dlapiper.com

-and-

Shant K. A. Eulmessekian (NY No. 6094668)
DLA Piper LLP (US)
2000 Avenue of the Stars, Suite 400 North Tower
Los Angeles, California 90067
Telephone: (310) 595-3000
Facsimile: (310) 595-3300
Email: shant.eulmessekian@us.dlapiper.com

Co-Counsel to Fund Debtor

ORRICK, HERRINGTON & SUTCLIFFE LLP
David Litterine-Kaufman (admitted pro hac vice)
Evan C. Hollander (admitted pro hac vice)
Nicholas Poli (admitted pro hac vice)
Alexandra Zablocki (admitted pro hac vice)
51 West 52nd Street
New York, NY 10019-6142
Telephone: (212) 506-5000
Facsimile: (212) 506-5151
E-mail:dlitterinekaufman@orrick.com
echollander@orrick.com
npoli@orrick.com

-and-

Nicholas Sabatino (admitted pro hac vice)
400 Capitol Mall
Suite 300
Sacramento, CA 95814-4497
Telephone: (916) 447-9200
Facsimile: (916) 329-4900
E-mail: nsabatino@orrick.com

Proposed Co-Counsel to the Fund Debtor

Exhibit A

Proposed Order

N THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
Apple Tree Life Sciences, Inc., *et al*.,[1]	)	Case No. 25-12177 (LSS)
Debtors.	)	Jointly Administered
	)	**Related to Docket No. 1232**

ORDER PURSUANT TO 11 U.S.C. § 327(a) AUTHORIZING AND APPROVING THE EMPLOYMENT AND RETENTION OF ORRICK, HERRINGTON & SUTCLIFFE LLP AS CO-COUNSEL TO DEBTOR ATP LIFE SCIENCE VENTURES, L.P., EFFECTIVE AS OF SEPTEMBER 28, 2026

Upon consideration of the application (the "Application")[2] of Debtor ATP Life Science Ventures, L.P. (the "Fund Debtor") in the Chapter 11 Cases of the above-captioned debtors and debtors-in-possession (the "Debtors") for entry of an order authorizing and approving the employment and retention of Orrick, Herrington & Sutcliffe LLP ("Orrick") as co-counsel to the Fund Debtor, effective as of September 28, 2026, and upon the Litterine-Kaufman Declaration and Lynch Declaration, as annexed thereto, and it appearing that proper notice of the Application has been given and that no further notice or hearing is required, and the Court being satisfied based on the representations made in the Application and declarations that (i) Orrick represents no interest adverse to the Debtors' estates, creditors, or equity holders, (ii) Orrick is a "disinterested person" as that term is defined in section 101(14) of the Bankruptcy Code, and (iii) the employment of

[1] The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors' service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.

[2] Capitalized terms used but not otherwise defined herein have the meanings given to them in the Application.

Orrick is necessary and would be in the best interest of the Fund Debtor and its estate, and after due deliberation, and sufficient cause appearing therefor, it is hereby

ORDERED that the Application is granted as set forth herein; and it is further

ORDERED that in accordance with section 327(a) of title 11 of the United States Code (the "Bankruptcy Code"), the Fund Debtor is hereby authorized and empowered to retain Orrick as co-counsel, effective as of September 28, 2026, to represent the Fund Debtor in its case under chapter 11 of the Bankruptcy Code in accordance with the terms set forth in the Application; and it is further

ORDERED that Orrick shall be compensated in accordance with the procedures set forth in sections 330 and 331 of the Bankruptcy Code, the Bankruptcy Rules, the Local Rules, and any applicable procedures and orders of the Court; and it is further

ORDERED that Orrick shall make a reasonable effort to comply with the U.S. Trustee's requests for information and additional disclosures as set forth in the *Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses Filed under 11 U.S.C. § 330 by Attorneys in Larger Chapter 11 Cases Effective as of November 1, 2013*, both in connection with the Application and the interim and final fee applications to be filed by Orrick in these Chapter 11 Cases; and it is further

ORDERED that Orrick will review its files periodically during the pendency of the Chapter 11 Cases to ensure that no conflicts or other disqualifying circumstances exist or arise and, if any new relevant facts or relationships are discovered or arise, Orrick will use reasonable efforts to identify such further developments and will promptly file a supplemental declaration, as required by Bankruptcy Rule 2014(a); and it is further

ORDERED that Orrick shall use its reasonable efforts to avoid any duplication of services provided by any of the Fund Debtor's other retained professionals in these Chapter 11 Cases; and it is further

ORDERED that Orrick will not charge a markup to the Fund Debtor with respect to fees billed by contract attorneys who are hired by Orrick to provide services to the Fund Debtor and shall ensure that any such contract attorneys are subject to conflict checks and disclosures in accordance with the requirements of the Bankruptcy Code and the Bankruptcy Rules. For the avoidance of doubt, Orrick shall not share fees with existing or future contract attorneys who advise the Fund Debtor or enter into fee-sharing arrangements with such contract attorneys; and it is further

ORDERED that Orrick will provide ten (10) days' advance written notice of any rate increases to the Fund Debtor, the U.S. Trustee, the other Debtors, and any committee appointed by this Court before any increases in the rates set forth in the Application or the Litterine-Kaufman Declaration are implemented and shall file such notice with the Court; *provided, however*, that in the event Orrick attorneys responsible for this matter do not have sufficient advance notice of such rate increases, Orrick shall provide notice to the Fund Debtor, the U.S. Trustee, the other Debtors and any committee appointed by this Court within a reasonable time after the information regarding rate increases becomes available to the Orrick attorneys responsible for this matter. The Fund Debtor, the other Debtors, the U.S. Trustee, any committee appointed by this Court and all parties in interest retain all rights to object to any rate increase on all grounds including, but not limited to, the reasonableness standard provided for in section 330 of the Bankruptcy Code, and the Court retains the right to review any rate increase pursuant to section 330 of the Bankruptcy Code; and it is further

ORDERED that during the course of the Chapter 11 Cases, this Court has and shall retain exclusive jurisdiction to hear and determine all matters arising from the implementation of this Order.